» Articles » PMID: 31950251

Leaflet Thickening and Stent Geometry in Sutureless Bioprosthetic Aortic Valves

Overview
Journal Heart Vessels
Date 2020 Jan 18
PMID 31950251
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Underexpansion of transcatheter heart valves and the surgically implanted Perceval sutureless aortic valve bioprosthesis has been suggested as an underlying mechanism for hypo-attenuated leaflet thickening (HALT). This was a single-center prospective observational study that included 47 patients who underwent surgical aortic valve replacement with the Perceval sutureless bioprosthesis (LivaNova, London, United Kingdom) from 2012 to 2016 and were studied by four-dimensional cardiac computed tomography (CT). The association between overall and regional expansion and the prevalence of HALT was analyzed. In total 46 patients were included in the analysis. HALT was found in 39.1% of patients and the mean overall prosthesis expansion was 75.5 ± 5.2% (range 64.6-84.8%). Overall expansion did not differ between patients with HALT compared with patients without HALT (mean overall expansion 74.0 ± 5.2% vs. 76.5 ± 5.0%, P = 0.11). The prevalence of HALT was lower in patients with overall expansion > 80% compared to patients with expansion < 80% expansion though not significantly (20% vs. 44.4%, P = 0.16). None or trivial regional underexpansion was found in 94.7% of coronary cusps. There was no significant association between regional underexpansion and the prevalence of HALT (mean coronary cusp angle 120 ± 8° vs. 119 ± 10°, P = 0.53). The prevalence of HALT and overall underexpansion was high in the Perceval sutureless bioprosthetic valve. Overall underexpansion was not associated with HALT. Whether severe overall underexpansion increases the risk for HALT requires further study. Regional underexpansion was uncommon in the Perceval sutureless bioprosthetic valve and not associated with HALT.Clinical trial registration Unique identifier: NCT03753126 (http://www.clinicaltrials.gov).

Citing Articles

Comparison of apixaban versus aspirin for the prevention of latent bioprosthetic aortic valve thrombosis: study protocol for a prospective randomized trial.

Kopjar T, Gasparovic H, Hrabak Paar M, Lovric D, Cerina P, Tokic T Trials. 2024; 25(1):324.

PMID: 38755709 PMC: 11097528. DOI: 10.1186/s13063-024-08175-w.


Early thrombus formation including hypo-attenuated leaflet thrombosis after surgical bioprosthetic aortic valve replacement.

Kono T, Takagi K, Takaseya T, Fukuda T, Saku K, Zaima Y Gen Thorac Cardiovasc Surg. 2024; 72(9):568-576.

PMID: 38403822 DOI: 10.1007/s11748-024-02010-4.


Avoiding oversizing in sutureless valves leads to lower transvalvular gradients and less permanent pacemaker implants postoperatively.

Szecel D, Lamberigts M, Rega F, Verbrugghe P, Dubois C, Meuris B Interact Cardiovasc Thorac Surg. 2022; 35(2).

PMID: 35689614 PMC: 9272061. DOI: 10.1093/icvts/ivac157.

References
1.
Cerillo A, Amoretti F, Mariani M, Cigala E, Murzi M, Gasbarri T . Increased Gradients After Aortic Valve Replacement With the Perceval Valve: The Role of Oversizing. Ann Thorac Surg. 2018; 106(1):121-128. DOI: 10.1016/j.athoracsur.2017.12.044. View

2.
Ruile P, Jander N, Blanke P, Schoechlin S, Reinohl J, Gick M . Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation. Clin Res Cardiol. 2016; 106(2):85-95. DOI: 10.1007/s00392-016-1052-3. View

3.
Pache G, Schoechlin S, Blanke P, Dorfs S, Jander N, Arepalli C . Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J. 2015; 37(28):2263-71. DOI: 10.1093/eurheartj/ehv526. View

4.
Budoff M, Cohen M, Garcia M, Hodgson J, Hundley W, Lima J . ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance. Circulation. 2005; 112(4):598-617. DOI: 10.1161/CIRCULATIONAHA.105.168237. View

5.
Kanjanauthai S, Pirelli L, Nalluri N, Kliger C . Subclinical leaflet thrombosis following transcatheter aortic valve replacement. J Interv Cardiol. 2018; 31(5):640-647. DOI: 10.1111/joic.12521. View